Pfizer Inc. (PFE)
| Market Cap | 229.50B |
| Revenue (ttm) | 100.33B |
| Net Income (ttm) | 31.37B |
| Shares Out | 5.64B |
| EPS (ttm) | 5.47 |
| PE Ratio | 7.43 |
| Forward PE | 10.96 |
| Dividend | $1.61 (3.96%) |
| Ex-Dividend Date | Jan 26, 2023 |
| Volume | 16,650,551 |
| Open | 40.86 |
| Previous Close | 40.81 |
| Day's Range | 40.31 - 40.91 |
| 52-Week Range | 39.23 - 56.32 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 53.10 (+30.56%) |
| Earnings Date | May 2, 2023 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zit... [Read more]
Financial Performance
In 2022, Pfizer's revenue was $100.33 billion, an increase of 23.43% compared to the previous year's $81.29 billion. Earnings were $31.37 billion, an increase of 42.74%.
Financial StatementsAnalyst Forecast
According to 29 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $53.1, which is an increase of 30.56% from the latest price.
News
7 High-Yield Dividend Stocks to Compete Against Rising Yields
Although passive income has always been a strong component of a well-balanced portfolio, investors may want to pay particular attention to high-yield dividend stocks to buy. Should the Federal Reserve...
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May...
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote
FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.
Biotech experts wary of Pfizer cutting Seagen workforce — but history reveals silver lining
Seattle-area biotech experts are eying the past with a wary eye in the wake of this week's news that Pfizer plans to acquire Bothell, Wash.
Is Pfizer Stock Undervalued At $40?
Pfizer stock (NYSE: PFE) has seen a fall of 21% this year, compared with 2% returns for the broader S&P500 index.
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOKYO , March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, Pre...
FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people
Paxlovid is recommended for people over 50 or those with medical conditions like high blood pressure or diabetes that place them at a greater risk of Covid.
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID™
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data s...
FDA committee says benefits outweigh risks for Pfizer's Paxlovid
A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer's PFE COVID antiviral Paxlovid outweigh the risks in adults who are at high risk of severe disease. The FDA is ...
FDA panel to meet Thursday to discuss full approval of Paxlovid
A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill developed by Pfizer PFE to treat high-risk C...
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.
Pfizer's Latest Acquisition Strengthens the Case for PFE Stock
On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share.
Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs
Five of Pfizer's drugs will cost less for Medicare recipients starting next month as part of President Joe Biden's plan to lower prescription drug cost.
FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children
The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third...
3 Vaccine Stocks to Watch for Their Post-Pandemic Moves
During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.
FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5
The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults
FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.
Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio
Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.
NEW YORK , March 14, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. ("Seagen" or the "Company"...
How Pfizer's $43 billion acquisition of Seagen could impact the biotech industry in Seattle
Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed.
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (Nas...